Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.
PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.
From Left to Right: Martin B. Leon, MD, Andrew Cleeland and Juan F. Granada, MD, at TCT 2025 in San Francisco.
The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco.
Tim Andrews, 67, is still alive and is back on the waiting list for a human donor. However, the success of his highly experimental procedure means more patients are scheduled to get genetically modified animal organs.
A new study published in JAMA, which looked at fee-for-service Medicare records from 2013–2023, found that overall participation has trended upward. However, the details paint a complicated picture.
Christian M. Spaulding, MD, PhD, discusses late-breaking data on the SELUTION SLR Drug-Eluting Balloon at TCT 2025.
The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.
His former colleagues say he was a "ceaseless champion for advancing the radiology industry" and that his contributions to the field "will be remembered with immense gratitude.”
The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.